CHICAGO, IL—Use of an investigational endothelin receptor antagonist in patients with resistant hypertension has a significant impact on both automated office and 24-ambulatory blood pressure when ...
Brief review of the endothelin, prostacyclin, and nitric oxide pathways and how they are targeted in patients with PH or PAH. Transcript Charles D. Burger, MD: The FDA-approved therapies for pulmonary ...
Please provide your email address to receive an email when new articles are posted on . CHICAGO — Aprocitentan, a dual endothelin antagonist, was superior to placebo for BP lowering and was well ...
CHICAGO -- Two novel drugs showed promise for blood pressure (BP) lowering in people with treatment-resistant hypertension, according to research presented at the American Heart Association (AHA) ...
Panelists discuss how the pathophysiology of pulmonary arterial hypertension involves complex mechanisms across multiple genetic and treatment pathways, with over 20 identified genes and four major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results